Abstract
A metastatic phenotype can be induced in benign rat mammary cells (Rama 37 cells) by transfecting them with metastasis-inducing DNAs (Met-DNAs). Stable transfection of Met-DNAs increases the level of the metastasis-associated protein, osteopontin. Randomly picked clonal cell lines have been established from the pool of Rama 37 cells transfected with one metastasis-inducing DNA, C9-Met-DNA. In these cell lines, moderate correlation is observed between the copy number of C9-Met-DNA and their metastatic potential (linear regression coefficient, R2=0.48). A very close correlation is observed between the cell lines’ metastatic potential in vivo and the osteopontin mRNA levels in vitro (R2=0.74), but not with another metastasis-associated protein in this system, S100A4 (R2=0.21). A close correlation is also observed between osteopontin mRNA levels and the adhesive potential (R2=0.91) of the cells, but not with their growth rate in vitro (R2=0.03). These observations support the previous suggestion that osteopontin is the direct effector of C9-Met-DNA and that the presence of C9-Met-DNA is necessary, if not sufficient, for the induction of metastasis in vivo in this system. Additionally, these results suggest that Rama 37 cells with increased osteopontin mRNA levels become metastatic not through an increased growth rate, but through an increase in cellular adhesiveness.
Similar content being viewed by others
Main
Breast cancer is one of the leading causes of death from cancer in women (Pisani et al, 1999a, 1999b). More specifically, it is the metastasis of the primary breast tumour to distant sites in the body that causes the majority of deaths attributed to breast cancer. Metastasis of breast tumours is frequently life threatening with only 20% of patients diagnosed with metastatic disease surviving after 5 years (American Cancer Society, 1998). One assay for genes that can induce metastasis in breast cells uses the karyotypically stable rat mammary epithelial cell line Rama 37, which is derived from a benign 1, 12 dimethyl benz(a) anthracene-induced mammary tumour as a recipient (Dunnington et al, 1983). The Rama 37 cell line yields nonmetastasising tumours when injected into the mammary fat pads of syngeneic rats. However, when this cell line is transfected with certain genes, the primary tumours metastasise to the lungs and lymph nodes. Transfected genes that can induce metastasis in this system include those for S100A4 (Davies et al, 1993), osteopontin (Oates et al, 1996) and Cutaneous Fatty Acid Binding Protein (Jing et al, 2000), but not conventional growth-promoting genes such as Ha-ras (Davies et al, 1994) and FGF2 (Davies et al, 1996). The products of those genes, which can induce a metastatic phenotype when transfected into Rama 37 cells, have also been shown to occur at higher levels in malignant than in benign, human breast tumours (Jing et al, 2000; Platt-Higgins et al, 2000; Rudland et al, 2002) and for S100A4 and osteopontin are associated with premature death of patients from metastatic breast disease (Platt-Higgins et al, 2000; Rudland et al, 2002).
In an attempt to identify further regions of the genome that may be involved in metastasis, restriction enzyme-fragmented DNA of the malignant cell line Ca2-83 from a metastatic breast cancer was transfected into the Rama 37 cell line and tested for metastatic capacity in the animal model system (Davies et al, 1994). Six fragments of metastasis-inducing DNA (Met-DNA) were subsequently identified which could induce a metastatic phenotype when transfected into the Rama 37 cell line. All Met-DNAs separately induced the expression of osteopontin (Chen et al, 1997), in at least one case (C9-Met-DNA) by the removal of an inhibitory transcription factor Tcf-4 from the osteopontin promoter (El-Tanani et al, 2001). Although the six Met-DNAs produced different elevated levels of osteopontin mRNA in the resultant pools of transfectants, there was no obvious correlation between these levels and the number of animals bearing metastases, suggesting that osteopontin may be acting indirectly (Chen et al, 1997). Moreover, although the mechanism by which osteopontin overexpression induces a metastatic phenotype in the Rama 37 system is unknown, there is evidence to link osteopontin with many of the cellular events that are involved in metastasis, such as avoidance of the immune system, cellular migration (Liaw et al, 1995; Singh et al, 1995; Tuck et al, 2000), invasion (Tuck, 1999) and adhesion (Liaw et al, 1994; Barry et al, 2000).
In this report, nine clonal cell lines have been established from the original pool of C9-Met-DNA-transfected Rama 37 cells and the molecular and cellular characteristics of each of these clonal cell lines have been investigated. The results now show that osteopontin is the direct effector of metastasis in this system. Additionally, a direct correlation between osteopontin mRNA levels, metastatic potential and cellular adhesion has been shown for the first time, leading to the suggestion that osteopontin induces metastasis in Rama 37 cells, at least in part, by a process reflected in their increased adhesiveness on plastic substrata and not by providing any growth advantage over the untransfected Rama 37 cells.
Materials and methods
Cell culture
All cell lines were maintained as described previously (Dunnington et al, 1983) in a humidified atmosphere of 90% (v v−1) air and 10% (v v−1) CO2 in routine medium (RM) (Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Paisely, Scotland) with 5% (v v−1) foetal calf serum (FCS) (Sigma, Dorset, UK), 50 ng ml−1 insulin and hydrocortisone). The control cell line Rama 800 was obtained from a transplantable rat mammary tumour (Jamieson and Rudland, 1990). Passaging of cells at a 1 : 8 dilution was carried out at 70–80% confluence using trypsin in EDTA, 0.05% (v v−1).
Establishment and testing of clonal cell lines
Clonal cell lines were established from the pool of Rama 37 cells transfected with C9-Met-DNA by plating approximately 10 000 cells in 9 cm diameter dishes. After 1 week, colonies derived from single cells were harvested by placing over the colony a 4 mm diameter disc of Whatman filter paper soaked in trypsin 0.05% (v v−1) in EDTA and incubating for 10 min at 37°C. The discs of paper with the cells attached were subsequently placed in one well of a 24-well plate in cloning medium (CM) (45% (v v−1) DMEM (Gibco BRL), 10% (v v−1) FCS (Sigma), 45% (v v−1) RPMI (Gibco BRL), 50 ng ml−1 hydrocortisone and insulin). When there were sufficient cells to be plated into 4, 9 cm diameter Petri dishes, they were transferred and maintained in RM. Plating efficiency was determined by plating the cell lines at a known density (20 000–30 000 cells per dish) in conditioned media generated from the RM of cells that had been growing exponentially in a 9 cm diameter plate for 3 days. After plating and incubation for 15 min at 37°C to allow cells to adhere to the plate, the cells were removed from the plate with trypsin/EDTA solution and counted in a Coulter counter. Plating efficiency was calculated as the percentage of cells that had adhered after 15 min. Three independent experiments were carried out in triplicate and error bars represent the standard deviation of the three separate experiments. Cell growth assays were carried out by plating a known density of cells (5–10 000 per well) in 24-well plates. Every day for 6 days, cells in a set of triplicate wells were completely removed by trypsinisation and counted in a Coulter counter. Growth curves were plotted and the gradients of the curves were obtained using linear regression analysis. Growth rates were subsequently represented as a percentage of that for the Rama 37 cell line. Experiments were carried out three times in triplicate and the error bars represent the standard deviation of three separate experiments.
Assay for metastasis
Metastasis assays were carried out as described previously (Dunnington et al, 1983). Cells (2 × 106) to be assayed, suspended in 0.2 ml phosphate-buffered saline (PBS), were injected into the right inguinal mammary fat pads of approximately 20 female Furth Wistar rats of 6–10 weeks of age. Animals were observed every 3 days and killed after 3 months. The primary tumour and lungs of each animal were then fixed in Methacarn (60% (v v−1) methanol, 10% (v v−1) acetic acid and 30% (v v−1) Inhibisol) and embedded in paraffin wax. Sections of 5 μm were then cut and stained with haematoxylin and eosin. Analysis of the stained lung sections allowed individual animals to be scored positive or negative for lung metastasis by two observers. Metastatic potential of the cell lines was expressed as the percentage of tumour-bearing animals exhibiting lung metastases. Animals were maintained under UK Home Office Project Licence no. 40/1515 to Professor PS Rudland in accordance with the guidelines set down by the United Kingdom Coordinating Committee for Cancer Research.
Northern and Southern blotting
DNA and RNA from the cell lines were isolated by ultracentrifugation through caesium chloride gradients of guanidine isothiocyanate cell extracts, as described previously (Coombs et al, 1990; Anandappa et al, 1994). Southern transfer was carried out as described in Sambrook et al (1989). Ten μg of EcoR1-digested genomic DNA was resolved on a 0.8% (w v−1) agarose gel and blotted overnight on to Hybond-N membrane (Amersham Pharmacia, Buckinghamshire, UK) in 20 × SSC. DNA was fixed on the membrane by exposure to UV light. RNA for Northern blotting was resolved on a 0.8% (w v−1) formaldehyde agarose gel and blotted onto Hybond-N membrane (Amersham Pharmacia) in 10 × SSC. RNA was fixed onto the membrane by exposure to UV light. Probes radioactively labelled with α-[32P]dCTP (ICN, Hampshire, UK) (specific activity >1 × 108 d.p.m μg−1 DNA) were generated for Northern and Southern blotting using a random primed labelling kit (Roche Molecular Chemicals, Hertfordshire, UK). The 1500 bp osteopontin cDNA probe was obtained by digestion of the pBKCMV-OPN plasmid (Oates et al, 1996) with restriction enzymes Xba1 and Kpn1. The 300 bp S100A4 cDNA was a PCR product of full-length rat S100A4 cDNA obtained from Dr I Hickson (University of Liverpool, UK). The 1000 bp C9-Met-DNA probe was obtained by digestion of the pKS-C9-Met-DNA plasmid (Chen et al, 1997) with HindIII. Hybridisation for Northern and Southern blots was carried out at 42°C in formamide buffer (5 × SSC, 50% (v v−1) formamide, 1 × Denhardt's solution (Sambrook et al, 1989), 5% (w v−1) dextran sulphate and 3 μg ml−1 sonicated salmon sperm DNA). After washing the membranes consecutively with: (1) 2 × SSC, 0.1% (w v−1) sodium dodecyl sulphate (SDS); (2) 0.2 × SSC, 0.1% (w v−1) SDS; and (3) 0.1 × SSC, 0.1% (w v−1) SDS, hybridisation signals were visualised by exposing the wrapped membrane to autoradiographic film for 6–72 h with an intensifying screen. Hybridisation signals were quantified using a Model XL 77CECCD video camera and MacIntosh IMAGE and PHOTO computer packages (NIH, Bethesda, MD, USA). C9-Met-DNA copy number was determined by comparing the intensity of C9-Met-DNA hybridised bands from the Rama cells to plasmid copy number controls on the same membrane. Although the amount of plasmid DNA and cellular DNA loaded onto the gel was different, comparison of relative intensities of hybridised bands of plasmid DNA and cellular DNA give a reliable estimate of copy number (Sambrook et al, 1989), as described previously (Davies et al, 1994; Oates et al, 1996; Chen et al, 1997). Equal loading of cellular DNA of the transformant and parental cell lines was indicated by equal sample intensity on the gel following electrophoresis and staining with ethidium bromide. There were no higher molecular weight bands hybridising to the OPN cDNA probe, indicating that digestion of genomic DNA by EcoR1 was complete in all cases. Osteopontin and S100A4 mRNA levels were normalised for differences in loading/transfer by dividing the intensity of the cDNA hybridised band by the intensity of the ethidium bromide-stained 28S ribosomal RNA band, rather than the intensity of an actin cDNA-hybridised band which could have possibly had its expression changed by C9-Met-DNA.
Statistical analysis
The Student's t-test and linear regression analysis to determine correlation coefficients were carried out using the Microsoft EXCEL package. The significance of the latter fit to a straight line was calculated, P values of less than 0.05 were considered statistically significant.
Results
Metastatic potential of clonal cell lines
Nine clonal cell lines were established from the original pool of Rama 37 cells transfected with C9-Met-DNA, they were termed R37C9VM followed by clone numbers. Within the set of clonal cell lines, various cellular morphologies were observed, ranging from tightly clustered cuboidal to a more elongated morphology (Table 1). Eight of the nine clonal cell lines produced primary tumours in all animals. The exception was the cell line R37C9VM6 which failed to produce primary tumours in any animals. Of the cell lines that produced primary tumours, lung metastases were detected in 32–71% of the tumour-bearing animals (Table 1). This range compares with the 24% lung metastases reported for the pool of Rama 37 cells transfected with C9-Met-DNA and with no metastases from the Rama 37 cell line (Oates et al, 1996; Chen et al, 1997) There was no correlation between cellular morphology and percent metastasis (Table 1).
Osteopontin and S100A4 mRNA levels
Northern blotting showed that six of the nine clonal cell lines had significantly higher levels of the correct size, 1.6 kb, osteopontin mRNA than the Rama 37 cell line, with the increase in levels ranging from 2.8- to 11.1-fold (Student's t-test, P⩽0.046) (Table 2) (Figure 1A, C). Osteopontin mRNA levels were corrected for differences in loading/transfer by normalisation to the 28S ribosomal RNA (Materials and Methods). The remaining three cell lines R37C9VM6, R37C9VM8 and R37C9VM29 failed to exhibit significantly elevated levels compared with the Rama 37 cell line. Furthermore, with the exception of R37C9VM18, all the clonal cell lines were shown to be significantly different from the C9-Met-DNA transfectant pool of Rama 37 cells (P<0.05) (Table 2). When the metastatic potential in vivo and the relative osteopontin mRNA levels in the cultured cell lines were plotted against each other, there was a significant linear relationship between them (linear regression analysis: R2=0.74, P=0.0007) (Figure 1D). The mRNA levels of another metastasis-inducing gene in this system, S100A4, failed to show significant differences for either the clonal cell lines or the pooled transfectants in comparison with that of the Rama 37 cell line (P>0.05) (Table 2) (Figure 1B, C). Furthermore, when the metastatic potential of the cell lines in vivo was plotted against S100A4 mRNA levels, there was no simple linear relationship between the two variables (linear regression analysis: R2=0.21, P=0.16) (Figure 1E). There was also no correlation between the levels of osteopontin mRNA and S100A4 mRNA (Table 3). The control cell line from a transplantable metastatic tumour, Rama 800 expressed both mRNAs at the correct size (Figure 1A, B).
C9-Met-DNA copy number
The number of copies of C9-Met-DNA integrated into the genome of each of the cell lines was assessed by Southern blotting. Six of the clonal cell lines from the C9-Met-DNA transfectants possessed approximately 80–170 copies of C9-Met-DNA fragments per haploid genome (R37C9VM3, R37C9VM8, R37C9VM13, R37C9VM14, R37C9VM18 and R37C9VM25) (Table 2) (Figure 2A). The remaining clonal cell lines possessed much lower C9-Met-DNA copy numbers of 0–10 (Table 2) (Figure 2A). Seven of the nine clonal cell lines had significantly higher numbers of C9-Met-DNA copies than the Rama 37 cell line (Student's t-test; P<0.05) (Table 2). The remaining two cell lines R37VM6 and R37C9VM29 did not have significantly higher levels. Moreover, the clonal cell lines R37C9VM3, VM8, VM13 and VM25 possessed significantly different levels of C9-Met-DNA compared to the C9-Met-DNA transfectant pool of Rama 37 cells (Student's t-test; P<0.05) (Table 2). When the number of integrated copies of C9-Met-DNA was plotted against the metastatic potential, there was a moderate but significant correlation (linear regression analysis: R2=0.48, P=0.02) (Figure 2B) (Table 3). There was also a moderate but significant correlation between the C9-Met-DNA copy number and the level of OPN mRNA (linear regression analysis: R2=0.43, P=0.03) but not with levels of S100A4 mRNA (linear regression analysis: R2=0.16, P=0.22) (Table 3).
Growth rates
Growth curves were constructed for each cell line in order to determine their average growth rate. All the cell lines that had been transfected previously with C9-Met-DNA showed a statistically significant reduction in growth rate over that obtained for the untransfected Rama 37 cells (Student's t-test; P<0.012). When the relative growth rates were plotted against their metastatic potential, there was no statistically significant correlation between the two variables (linear regression analysis: R2=0.2, P=0.17) (Table 3). There was also no correlation of growth rate with levels of osteopontin mRNA (R2=0.03, P=0.63) or of S100A4 mRNA (R2=0.01, P=0.76) (Table 3).
Adhesive potential
Adhesive potential of the C9-Met-DNA transfectants was determined from their plating efficiency over a 15-min period in conditioned medium exposed for 3 days to the growing transfectants (Materials and Methods). Seven of the nine C9-Met-DNA transfectants possessed a statistically increased plating efficiency over that of the untransfected Rama 37 cells (Student's t-test; P<0.002) (Figure 3A). The remaining two cell lines, R37C9VM6 and R37C9VM29 failed to show a significant increase. When the plating efficiency was plotted against the metastatic potential, there was a statistically significant linear correlation between these two variables (linear regression analysis: R2=0.73, P=0.0008) (Figure 3B) (Table 3). There was also a highly significant correlation of adhesive potential with levels of OPN mRNA (R2=0.91, P=6 × 10−6), but not with levels of S100A4 mRNA (R2=0.21, P=0.16) (Table 3). To test whether the conditioned medium or the cells were causing the increase in adhesiveness of the OPN-expressing transfectants, all the transfectants were retested for adhesive potential in fresh routine medium not exposed to cells. There was no significant difference in plating efficiency for any of the transformant or parental cell lines when tested in routine or conditioned media (Students’ t-test, P>0.05). Furthermore, under these conditions, there was also a statistically significant linear correlation between plating efficiency and metastatic potential (linear regression analysis, R2=0.78, P=0.00031), and plating efficiency and levels of OPN mRNA (R2=0.93, P=2 × 10−6) (not shown); the levels of correlation were similar to those observed earlier when transformant and parental cell lines were tested in their conditioned media rather than in fresh, unconditioned media.
Discussion
To assess the association of levels of osteopontin mRNA with metastasis and other molecular and cellular characteristics, a series of single-cell-cloned cell lines has been isolated from the original pool of C9-Met-DNA Rama 37 transfectants described by Chen et al (1997). That the C9-Met-DNA-transfected clonal cell lines possess a range of morphologies in culture and show different metastatic potentials in vivo suggests that the pool of C9-Met-DNA-transfected Rama 37 cells is a mixed population of cell types. This suggestion may explain why a linear correlation between the osteopontin mRNA levels and metastatic potential of the various pooled transfectants produced from the other Met-DNAs (C6-Met-DNA, etc.), although significantly increased, was not observed (Chen et al, 1997). For example, the Rama 37 cells transfected with C6-Met-DNA induced a relatively high level of metastasis (50%), but the increase in osteopontin mRNA was relatively modest (1.6-fold), whereas Rama 37 cells transfected with C9-Met-DNA induced a lower level of metastasis (23%), but showed a relatively high increase in osteopontin mRNA (4.4-fold).
Previously, osteopontin mRNA levels have been suggested to be the effector of all the Met-DNA fragments, including C9-Met-DNA in the induction of metastasis (Oates et al, 1996; Chen et al, 1997). Furthermore, the levels of osteopontin mRNA have been shown to reflect the levels of osteopontin protein in Met-DNA-transfected Rama 37 cells (Oates et al, 1996; Chen et al, 1997; El-Tanani et al, 2001). Now the dose-dependent relationship observed between osteopontin mRNA levels in culture and metastatic potential in vivo for the clonal cell lines provides strong evidence that, in the case of these C9-Met-DNA-transfected clonal cell lines, metastatic potential in vivo is linearly correlated with the osteopontin mRNA levels found in the cultured cells. Hence, it is highly probable that increases in the relative amounts of osteopontin protein produced by the tumour cells is the final effector of at least C9-Met-DNA. Moreover, another gene known to induce metastasis in Rama 37 cells, that for S100A4 (Davies et al, 1993), does not have significantly higher levels of mRNA in the C9-Met-DNA clonal cell lines than in the untransfected Rama 37 cell line. Thus, it is highly likely that increased osteopontin mRNA levels (and hence protein) are the direct cause of the elevated metastatic potential in the C9-Met-DNA-transfected Rama 37 cells. This conclusion is substantiated by experiments that show overexpression of osteopontin by stable transfection of an expression vector in Rama 37 cells induces a metastatic phenotype (Oates et al, 1996). Furthermore, the association of osteopontin overexpression both with tumour progression and with metastasis has been documented in other in vivo animal models (Craig et al, 1990; Gardner et al, 1994; Feng et al, 1995; Behrend et al, 1995) and in human studies (Singh et al, 1997; Tuck et al, 1997; Rudland et al, 2002).
Both the loss and gain of cell–cell adhesion is important for metastasis. For example, in the early stages of metastasis, the cell adhesion molecule E-cadherin is often lost, allowing cells to escape from the primary tumour (Christofori and Semb, 1999). However, at more advanced stages of malignancy, E-cadherin appears to be re-expressed (Bukholm et al, 2000). In this report, osteopontin mRNA levels are linearly correlated with cellular adhesive potential in this set of clonal C9-Met-DNA-transfected Rama 37 cell lines. This result suggests that the mechanism by which the increased osteopontin levels cause increased metastatic potential in these cells is by increasing cellular adhesiveness, at least in part, although other mechanisms cannot be excluded. Since there was no difference in the plating efficiency when transformant and parental cell lines were tested in their conditioned or fresh unconditioned media, the increase in adhesiveness of the transfectants arises almost exclusively from the cells themselves and not from material secreted into the conditioned medium. Increases in cellular adhesion could allow attachment of the tumour cells to vessel walls before extravasation and migration to their chosen site of metastasis. This hypothesis is supported by the evidence that osteopontin has also been shown to mediate cellular adhesion of several different types of cells including human breast cancer cells, transformed NIH 3T3 cells and erythroleukaemic cells (Liaw et al 1994; Barry et al, 2000).
During the process of metastasis, intercellular contact mediated through the cell adhesion molecule E-cadherin appears to prevent apoptosis (Kantak and Kramer, 1998; Day et al, 1999). There is growing evidence to suggest that osteopontin may also inhibit apoptosis during metastasis. The inhibition of apoptosis by OPN has been shown in a variety of cell types including human breast cancer cells and endothelial cells (Lopez et al, 1996; Khan et al, 2002). Additionally, osteopontin-deficient vascular smooth muscle cells show increased apoptosis and decreased adherence. This not only provides further evidence for the role of osteopontin in cellular adherence but also in the inhibition of apoptosis (Weintraub et al, 2000). The mechanism by which osteopontin inhibits apoptosis is thought to be via multiple ligand receptor interactions in response to various proapoptotic signals (Denhardt et al, 2001). Therefore, osteopontin-mediated adhesion of the tumour cells could be operating in the same manner as re-expressed E-cadherin. Initially apoptosis is inhibited, allowing the tumour cells in the circulation to survive and then through increasing cell–cell adhesion, the tumour cells become attached to blood vessel walls ready for extravasation.
Other properties that can be affected by an increase in osteopontin expression include an increase in matrix metalloproteinase expression (Teti et al, 1998), an increase in cellular migration (Liaw et al, 1994; Tuck et al, 2000) and a protective capacity of tumour cells from macrophage-mediated nitric oxide attack (Denhardt and Chambers, 1994; Feng et al, 1995). These potential changes and others have not been assayed in the present system, and it is possible that all, or a combination of properties, not just increased cellular adhesion are responsible for the cell lines with high levels of osteopontin mRNA becoming metastatic in vivo. However, the results clearly demonstrate that the C9-Met-DNA-transfected cells have not simply gained a selective growth advantage over untransfected Rama 37 cells, since the growth rates of the clonal cell lines in vitro do not correlate separately with either metastatic potential or osteopontin mRNA levels. Moreover, the benign untransfected Rama 37 cell line possesses a significantly faster growth rate in vitro than the majority of the clonal cell lines and the latent period before the tumours appear in vivo is similar in the parental Rama 37 cell line and in the C9-Met-DNA-transfected clonal cell lines, both results mitigating against growth advantage being the cause of metastasis in this system.
That there is only a moderately significant linear relationship between metastatic potential and C9-Met-DNA copy number suggests that, although the presence of C9-Met-DNA is essential, it may not necessarily be sufficient for the transfected Rama 37 cell to become metastatic in vivo. Digestion of genomic DNA by EcoR1 was complete in all cases, as described in Materials and Methods, so eliminating the possibility of anomalous numbers of integrated copies of transfected OPN cDNA being recorded. C9-Met-DNA has been postulated to act by the removal of the transcription factor Tcf-4 from the osteopontin promoter, where it acts normally to suppress osteopontin transcription (El-Tanani et al, 2001). For Tcf-4 to be removed from the osteopontin promoter by the C9-Met-DNA, the integrated copies of C9-Met-DNA in the chromatin need to be in a conformation that is accessible to proteins, that is unwound. This state would probably depend on their becoming integrated into a region of the genome of a Rama 37 cell that is actively transcribed. Different sites of integration of the concatamers of C9-Met-DNA (Chen et al, 1997) could explain the observation in this report that occasionally large numbers of integrated C9-Met-DNA fragments occur in transfected cells with low levels of osteopontin mRNA and a low metastatic potential (e.g. R37C9VM8).
To conclude, this report proves that the original pool of C9-Met-DNA-transfected Rama 37 cells is a mixed population of cells with various molecular and cellular characteristics. Moreover, the close association between osteopontin mRNA levels and metastatic potential of the C9-Met-DNA clonal cell lines provides further evidence that the direct effect of C9-Met-DNA is indeed mediated through the increase in osteopontin mRNA levels. Finally the pairwise linear correlations between metastatic potential, and both osteopontin mRNA levels and plating efficiency of the cells suggests that the mechanism by which osteopontin increases metastatic potential is mediated, at least in part, by increasing the adhesion of the tumour cells in this system.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
American Cancer Society (1998) Cancer Statistics. CA Cancer J Clin 48: 1–63
Anandappa SY, Winstanley JHR, Leinster S, Green B, Rudland PS, Barraclough R (1994) Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 69: 772–776
Barry ST, Ludbrook SB, Murrison E, Horgan CMT (2000) A regulated interaction between α5β1 integrin and osteopontin. Biochem Biophys Res Commun 267: 764–769
Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1995) Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann NY Acad Sci 760: 299–301
Bukholm IK, Nesland JM, Borresen-Dale AL (2000) Re-expression of E-cadherin α′-catenin and β-catenin, but not of γ-catenin, in metastatic tissue from breast cancer patients. J Path 190: 15–19
Chen HJ, Ke YQ, Oates AJ, Barraclough R, Rudland PS (1997) Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 14: 1581–1588
Christofori G, Semb H (1999) The role of the cell adhesion molecule E-cadherin as a tumour-suppressor gene. TIBS 24: 73–76
Coombs LM, Pigott D, Proctor A, Eydmann M, Denner J, Knowles MA (1990) Simultaneous isolation of DNA, RNA, and antigenic protein exhibiting kinase activity from small tumor samples using guanidine isothiocyanate. Anal Biochem 188: 338–343
Craig AM, Bowden GT, Chambers AF, Spearman MA, Greenberg AH, Wright JA, McLeod M, Denhardt DT (1990) Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 46: 133–137
Davies BR, Barraclough R, Rudland PS (1994) Induction of metastatic ability in a stably diploid benign rat mammary epithelial cell line by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 54: 2785–2793
Davies BR, Davies MPA, Gibbs FEM, Barraclough R, Rudland PS (1993) Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 8: 999–1008
Davies BR, Fernig DG, Barraclough R, Rudland PS (1996) Effect on tumorigenicity and metastasis of transfection of a diploid benign rat mammary epithelial cell line with DNA corresponding to the mRNA for basic fibroblast growth factor. Int J Cancer 65: 104–111
Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, Day KC (1999) E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Sci 274: 9656–9664
Denhardt DT, Chambers AF (1994) Overcoming obstacles to metastasis – defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 56: 48–51
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as means to cope with environmental insults: regulation of inflammation, tissue remodeling and cell survival. J Clin Invest 107: 1055–1061
Dunnington DJ, Hughes CM, Monaghan P, Rudland PS (1983) Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 71: 1227–1240
El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS (2001) Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 61: 5619–5629
Feng B, Rollo EE, Denhardt DT (1995) Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by targeted ribozyme. Clin Exptl Metast 13: 453–462
Gardner HAR, Berse B, Senger DR (1994) Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9: 2321–2326
Jamieson S, Rudland PS (1990) Identification of metastatic variants generated by transfection of a non metastatic rat mammary epithelial cell line with DNA from a metastatic rat mammary cell line. Am J Pathol 137: 629–641
Jing C, Beesley C, Foster CS, Rudland PS, Fujii H, Ono T, Chen H, Smith PH, Ke Y (2000) Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer. Cancer Res 60: 2390–2398
Kantak SS, Kramer RH (1998) E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 273: 16953–16961
Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT (2002) Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728–736
Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM (1994) Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74: 214–224
Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM (1995) The adhesive and migratory effects of osteopontin are mediated via distinct cell-surface integrins – role of αvβ3 in smooth-muscle cell migration to osteopontin in vitro. J Clin Invest 95: 713–724
Lopez CA, Carroll AG, Denhardt DT, Lupu R (1996) Effect of heregulin on proliferation and expression of apoptosis-related genes: interaction with osteopontin. Proc AACR Ann Mt 37: 22
Oates AJ, Barraclough R, Rudland PS (1996) The identification of osteopontin as a metastasis related gene product in a rodent mammary tumour model. Oncogene 13: 97–104
Pisani P, Parkin D, Bray F, Ferlay J (1999a) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18–29
Pisani P, Parkin DM, Bray F, Ferlay J (1999b) Erratum : estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 870–873
Platt-Higgins AM, Renshaw C, West CR, Winstanley JH, de Silva Rudland S, Barraclough R, Rudland PS (2000) Comparison of the metastasis-inducing protein S100A4 (p9Ka) with other prognostic markers in human breast cancer. Int J Cancer 89: 198–208
Rudland PS, Ollerhead G, Barraclough R (1989) Isolation of simian virus 40-transformed human mammary epithelial stem cell lines that can differentiate to myoepithelial-like cells in culture and in vivo. Dev Biol 136: 167–180
Rudland PS, Platt-Higgins A, El-Tanani M, de Silva Rudland S, Barraclough R, Winstanley JHR, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62: 3417–3427
Sambrook J, Fritsch EF, Maniatis T (1989) In Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press
Singh H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumour burden and decreased survival. Clin Cancer Res 3: 605–611
Teti A, Farina AR, Villanova I, Tiberio A, Tacconelli A, Sciortino G, Chambers AF, Gulino A, Mackay AR (1998) Activation of MMP-2 by human GCT23 giant cell tumour cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and shape change dependent. Int J Cancer 77: 82–93
Tuck AB (1999) Osteopontin induces increased invasiveness and plasminogen activator expression of mammary epithelial cells. Oncogene 18: 4236–4246
Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF (2000) Osteopontin-induced, integrin dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem 78: 465–475
Tuck AB, O'Malley FP, Singh H, Tonkin KS, Harris JF, Bautista D, Chambers AF (1997) Osteopontin and p53 expression are associated with tumour progression in a case of synchronous bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121: 578–584
Warburton MJ, Ormerod EJ, Monaghan P, Ferns S, Rudland PS (1981) Characterisation of a myoepithelial cell line derived from a neonatal rat mammary gland. J Cell Biol 91: 827–835
Weintraub AS, Schnapp LN, Lin XJ, Taubman MB (2000) Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis. Lab Invest 80: 1603–1615
Acknowledgements
We thank Mrs Angela Platt-Higgins and Mr Joe Carroll for assistance with histology and tumour collection, and the Cancer and Polio Research Fund for a studentship to VM and for consumables support.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Moye, V., Barraclough, R., West, C. et al. Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 90, 1796–1802 (2004). https://doi.org/10.1038/sj.bjc.6601683
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601683
Keywords
This article is cited by
-
Metastasis-inducing proteins are widely expressed in human brain metastases and associated with intracranial progression and radiation response
British Journal of Cancer (2016)
-
RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin
Oncogene (2008)
-
Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis
Oncogene (2006)
-
Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients
British Journal of Cancer (2006)